AGEN1423

DRUG2 trials

Sponsors

Bruno Bockorny, Weill Medical College of Cornell University

Conditions

Advanced Pancreatic Ductal AdenocarcinomaColorectal CancerColorectal Cancer MetastaticLiver MetastasesPancreatic CancerPancreatic Ductal Adenocarcinoma

Phase 2

AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC

Active, not recruitingNCT05632328

Bruno BockornyAdvanced Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma

Start: 2024-08-08End: 2027-04-01Target: 24Updated: 2026-07-09

Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases

RecruitingNCT06300463

Weill Medical College of Cornell UniversityColorectal Cancer, Colorectal Cancer Metastatic, Liver Metastases

Start: 2024-03-26End: 2027-12-01Target: 24Updated: 2026-05-15

Related Papers

A phase 2 study of botensilimab and AGEN1423, an anti-CD73-TGFβ-trap bifunctional antibody, in subjects with advanced pancreatic cancer.

Journal of Clinical Oncology2026-01-10

A phase 2 study of botensilimab and AGEN1423, an anti-CD73-TGFβ-trap bifunctional antibody, with or without chemotherapy in subjects with advanced pancreatic cancer.

Journal of Clinical Oncology2025-05-28